426. We thank the delegation of Bangladesh for sharing the LDCs request for extension of the transition period under Article 66.1 of the TRIPS Agreement, as well as the delegation of Uganda for the very eloquent intervention that recalled us the dire public health situations faced by LDCs.
427. Brazil would like to restate its longstanding position about the need for a balance between the interests of users and producers of intellectual property, so that our societies can reap the benefits from the system. If this is true for all areas dealt with in the TRIPS Agreement, it is even more pertinent when it relates to matters of public health.
428. We understand document IP/C/W/605 as a duly motivated request in the terms of Article 66.1 of the TRIPS Agreement. Thus, we are ready to support the request made by LDCs to extend the transition period under Article 66.1 for LDC Members with respect to pharmaceutical products and for waivers from the obligations of Articles 70.8 and 70.9 of the TRIPS Agreement.
